Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits

Rahim, Fakher; Arjmand, Babak; Shirbandi, Kiarash; Payab, Moloud; Larijani, Bagher

doi:10.21037/sci.2018.11.01

Cited by 22 publications

(25 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Study Alzheimer's disease Genetically or pharmacologically upregulating growth factors like brain-derived neurotrophic factor, IGF-1, nerve growth factor, and vascular endothelial growth factor that induce neurogenesis (25). (6,(35)(36)(37)(38)(39). Cardiovascular diseases are a major area of concern as they have a high incident, morbidity and mortality rate and include a variety of chronic conditions such as myocardial infarction (MI), atherosclerosis and aneurysms.…”

Section: Neural Precursor Cell Transplantation Effects On Myelinationmentioning

confidence: 99%

“…Stem cell therapy has also been studied in treating cancers, obesity, Parkinson's disease, hearing recovery, Alzheimer's disease, etc. ( 6 , 35 – 39 ). Cardiovascular diseases are a major area of concern as they have a high incident, morbidity and mortality rate and include a variety of chronic conditions such as myocardial infarction (MI), atherosclerosis and aneurysms.…”

Section: Personalized Regenerative Medicinementioning

confidence: 99%

See 1 more Smart Citation

Zebrafish for Personalized Regenerative Medicine; A More Predictive Humanized Model of Endocrine Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: Neural Precursor Cell Transplantation Effects On Myelinationmentioning

confidence: 99%

Section: Personalized Regenerative Medicinementioning

confidence: 99%

Zebrafish for Personalized Regenerative Medicine; A More Predictive Humanized Model of Endocrine Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…Cancer stem cells (CSCs) are immortal cells within a tumor that can self-renew and give rise to the bulk cancer cells [1,2]. Tumors with more CSCs are phenotypically more malignant and more likely to establish resistance to many treatment modalities [3,4].…”

Section: Introductionmentioning

confidence: 99%

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features

Man¹,

Cai²,

Dai³

2020

J. Cancer

View full text Add to dashboard Cite

Breast cancers can be classified into luminal A, luminal B, HER2 positive and triple-negative subtypes, each with a distinct therapeutic response. Tumor stemness drives cancer malignancy that challenges cancer control. Understanding the revolutionary relationships driven by tumor stemness among breast cancer subtypes is fundamental to identifying feasible therapeutic modalities for each breast cancer subtype. Utilizing the endogenous tRNA-processing system, we established a multiplexing CRISPR/dCas9 system in breast cancer cells, and applied it to a four-gene panel controlling cell potency, i.e., OCT4, KLF, MYC, SOX2. The stable cell strain, OKMS#1 was obtained through concomitantly over-expressing these genes in luminal A breast cancer cells. OKMS#1 cells showed increased invasion, proliferation and cancer stemness, shared similar drug response pattern with HER2 positive cells, and exhibited altered MAPK and enhanced NFkB signaling. This study contributes in providing an efficient multiplexing CRISPR/dCas9 system that enriches our genetic modulation tool box, and suggests that HER2 positive cells are potential progenitors of luminal A cells and that these two breast cancer subtypes may share similar treatment strategies once rewired between the two states. Our results also implicate that triple negative breast cancer cells, though sharing similar cancer stemness with HER2 positive cells, represent a distinct type of disease and require unique treatment solutions.

show abstract

“…However, it is unclear which type of stem cells is most effective in treating diabetes, and one study reported that severe infectious diseases occur after stem cell treatment [18]. Two meta-analyses explored the effects of stem cells on diabetes, but their findings were inconsistent [19,20]. Indeed, Rahim et al showed that stem cell therapy has a negative effect on C-peptide in patients with type 2 diabetes [19], but El-Badawy et al found that stem cell therapy can improve C-peptide levels [20].…”

mentioning

confidence: 99%

“…Two meta-analyses explored the effects of stem cells on diabetes, but their findings were inconsistent [19,20]. Indeed, Rahim et al showed that stem cell therapy has a negative effect on C-peptide in patients with type 2 diabetes [19], but El-Badawy et al found that stem cell therapy can improve C-peptide levels [20]. In addition, they studied changes in glycosylated hemoglobin (HbA1c) and C-peptide but did not systematically analyze fasting plasma glucose (FPG) levels, insulin requirements, or adverse events after stem cell therapy.…”

mentioning

confidence: 99%

The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis

Zhang¹,

Chen²,

Feng³

2020

Aging and disease

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic metabolic disease with high morbidity and mortality. Recently, stem cell-based therapy for DM has shown considerable promise. Here, we undertook a systematic review and meta-analysis of published clinical studies to evaluate the efficacy and safety of stem cell therapy for both type 1 DM (T1DM) and type 2 DM (T2DM). The PubMed, Cochrane Central Register of Controlled Trials, EMBASE, and ClinicalTrials.gov databases were searched up to November 2018. We employed a fixed-effect model using 95% confidence intervals (CIs) when no statistically significant heterogeneity existed. Otherwise, a randomeffects statistical model was used. Twenty-one studies met our inclusion criteria: ten T1DM studies including 226 patients and eleven T2DM studies including 386 patients. Stem cell therapy improved C-peptide levels (mean difference (MD), 0.41; 95% CI, 0.06 to 0.76) and glycosylated hemoglobin (HbA1c; MD,-3.46; 95% CI,-6.01 to-0.91) for T1DM patients. For T2DM patients, stem cell therapy improved C-peptide levels (MD, 0.33; 95% CI, 0.07 to 0.59), HbA1c (MD,-0.87; 95% CI,-1.37 to-0.37) and insulin requirements (MD,-35.76; 95% CI,-40.47 to-31.04). However, there was no significant change in fasting plasma glucose levels (MD,-0.52; 95% CI,-1.38 to 0.34). Subgroup analyses showed significant HbA1c and C-peptide improvements in patients with T1DM treated with bone marrow hematopoietic stem cells (BM-HSCs), while there was no significant change in the mesenchymal stem cell (MSC) group. In T2DM, HbA1c and insulin requirements decreased significantly after MSC transplantation, and insulin requirements and C-peptide levels were significantly improved after bone marrow mononuclear cell (BM-MNC) treatment. Stem cell therapy is a relatively safe and effective method for selected individuals with DM. The data showed that BM-HSCs are superior to MSCs in the treatment of T1DM. In T2DM, MSC and BM-MNC transplantation showed favorable therapeutic effects.

show abstract

Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits

Cited by 22 publications

References 42 publications

Zebrafish for Personalized Regenerative Medicine; A More Predictive Humanized Model of Endocrine Disease

Zebrafish for Personalized Regenerative Medicine; A More Predictive Humanized Model of Endocrine Disease

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features

The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About